New Zealand eyes public funding for advanced CAR T-cell cancer therapy within two years

New Zealand is on the cusp of a major breakthrough in cancer treatment with the potential public funding of CAR T-cell therapy within the next one to two years. This development, spearheaded by Wellington-based researchers at the Malaghan Institute of Medical Research, promises to bring a cutting-edge medical advancement into the local health system for the first time.

While patients like actor Sir Sam Neill have accessed this life-saving treatment through international clinical trials in Australia and the United States, the prospect of domestic availability marks a significant step forward. The therapy's success in international trials offers a beacon of hope for blood cancer patients in New Zealand, who have previously faced barriers to accessing such advanced care.

The Malaghan Institute's work is crucial in paving the way for CAR T-cell therapy's integration into New Zealand's healthcare landscape. This move underscores the nation's commitment to adopting world-class medical innovations and ensuring that its citizens have access to the most effective treatments available, regardless of geographical limitations.

“

New Zealand could begin publicly funding CAR T-cell therapy within the next one to two years, marking a major step toward bringing one of the world’s most advanced cancer treatments into the local health system for the first time.